Anti-PSMA Antibody, PE-Labeled

Only %1 left
Catalog #
101976
As low as $185 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

This human anti-PSMA antibody is a purified recombinant antibody, which is labeled with R-Phycoerythrin (PE). This antibody has been tested by flow cytometry assay for binding to human PSMA on the surface of the PSMA CHO Recombinant Cell Line (BPS Bioscience #79641).

Synonyms
Glutamate carboxypeptidase 2, FOLH1, FOLH, NAALAD1, PSM, GIG27, GIG27, FGCP, GCPII, mGCP, NAALADase I, PSM, Cell growth-inhibiting gene 27 protein, Folate hydrolase 1, Folylpoly-gamma-glutamate carboxypeptidase, Glutamate carboxypeptidase II
Product Info
Storage and Usage
Citations
Species
Human
Isotype
IgG1
Clonality
Monoclonal
Host Species/Expression System
HEK293
Purity

≥90%

Purification
Protein A affinity chromatography from HEK293 supernatants.
Format

Aqueous buffer solution

Formulation

8 mM Phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, 0.09% Sodium Azide, 0.2% BSA, and up to 20% glycerol. May contain a protein stabilizer.

UniProt #
Q04609
Label

PE is an oligomeric protein complex (270 kDa) from red algae that exhibits intensely bright red-orange fluorescence with excitation peak at 566 nm and an emission peak at 574 nm. The complex consists of six heterodimers, α subunit (18 kDa) and β-subunit (20 kDa), and an additional γ-subunit (34 kDa).

Background

PSMA (prostate-specific membrane antigen), also known as Folate hydrolase 1 or FOLH1, is an enzyme with folate hydrolase and peptidase activity. It is highly expressed in prostate cancer cells and is used as a diagnostic and prognostic indicator of prostate cancer. PSMA is used in the clinic as a target for PET (positron emission tomography) imaging in the detection and progression of prostate cancer, but radioactive analogs are used for the treatment of prostate cancer. It is also expressed in other tumor types and in a few normal tissues. PSMA is under extensive investigation as target for CAR-T cells and bi-specific antibodies-based cancer therapies.